Integra LifeSciences Stock Forecast, Price & News

+0.13 (+0.19 %)
(As of 06/15/2021 02:47 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,509 shs
Average Volume344,689 shs
Market Capitalization$5.90 billion
P/E Ratio34.87
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Integra LifeSciences logo

About Integra LifeSciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.26 out of 5 stars

Medical Sector

898th out of 2,100 stocks

Surgical & Medical Instruments Industry

88th out of 174 stocks

Analyst Opinion: 1.2Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Integra LifeSciences (NASDAQ:IART) Frequently Asked Questions

Is Integra LifeSciences a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Integra LifeSciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View analyst ratings for Integra LifeSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Integra LifeSciences?

Wall Street analysts have given Integra LifeSciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Integra LifeSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Integra LifeSciences' next earnings date?

Integra LifeSciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Integra LifeSciences

How were Integra LifeSciences' earnings last quarter?

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its quarterly earnings data on Tuesday, April, 27th. The life sciences company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.12. The life sciences company had revenue of $360.10 million for the quarter, compared to analyst estimates of $349.78 million. Integra LifeSciences had a trailing twelve-month return on equity of 15.63% and a net margin of 12.35%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.48 earnings per share.
View Integra LifeSciences' earnings history

How has Integra LifeSciences' stock price been impacted by Coronavirus?

Integra LifeSciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IART shares have increased by 51.2% and is now trading at $69.68.
View which stocks have been most impacted by COVID-19

When did Integra LifeSciences' stock split? How did Integra LifeSciences' stock split work?

Shares of Integra LifeSciences split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences stock prior to the split would have 200 shares after the split.

What guidance has Integra LifeSciences issued on next quarter's earnings?

Integra LifeSciences issued an update on its FY 2021 earnings guidance on Tuesday, June, 15th. The company provided earnings per share (EPS) guidance of $2.930-2.930 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.920. The company issued revenue guidance of $1.53 billion-1.54 billion, compared to the consensus revenue estimate of $1.53 billion.

What price target have analysts set for IART?

9 Wall Street analysts have issued 12 month target prices for Integra LifeSciences' stock. Their forecasts range from $50.00 to $88.00. On average, they expect Integra LifeSciences' stock price to reach $70.90 in the next year. This suggests a possible upside of 1.8% from the stock's current price.
View analysts' price targets for Integra LifeSciences
or view top-rated stocks among Wall Street analysts.

Who are Integra LifeSciences' key executives?

Integra LifeSciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 56, Pay $1.74M) (LinkedIn Profile)
  • Ms. Carrie L. Anderson, Exec. VP, CFO & Treasurer (Age 52, Pay $810.71k) (LinkedIn Profile)
  • Mr. Glenn G. Coleman, Exec. VP & COO (Age 53, Pay $927.95k) (LinkedIn Profile)
  • Mr. Robert T. Davis Jr., Exec. VP and Pres of Orthopedics & Tissue Technologies (Age 62, Pay $675.51k)
  • Mr. Michael J. McBreen, Exec. VP & Pres of Codman Specialty Surgical
  • Dr. Richard E. Caruso, Founder and Chairman Emeritus (Age 78)
  • Mr. Jeffrey Mosebrook, Sr. VP, Principal Accounting Officer & Corp. Controller (Age 45)
  • Dr. Kenneth E. Burhop Ph.D., Corp. VP & Chief Scientific Officer (Age 67) (LinkedIn Profile)
  • Mr. William Compton, Chief Information Officer & Sr. VP (LinkedIn Profile)
  • Mr. Sravan K. Emany, Sr. VP of Strategy & Investor Relations

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?

173 employees have rated Integra LifeSciences CEO Peter J. Arduini on Peter J. Arduini has an approval rating of 74% among Integra LifeSciences' employees.

Who are some of Integra LifeSciences' key competitors?

What other stocks do shareholders of Integra LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include The Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

What is Integra LifeSciences' stock symbol?

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra LifeSciences' major shareholders?

Integra LifeSciences' stock is owned by many different retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (7.72%), Janus Henderson Group PLC (5.51%), Eaton Vance Management (3.23%), Clearbridge Investments LLC (3.02%), Dimensional Fund Advisors LP (1.19%) and Geode Capital Management LLC (1.09%). Company insiders that own Integra LifeSciences stock include Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends for Integra LifeSciences

Which major investors are selling Integra LifeSciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Voloridge Investment Management LLC, MUFG Securities EMEA plc, Nisa Investment Advisors LLC, D. E. Shaw & Co. Inc., AQR Capital Management LLC, Jane Street Group LLC, and Fisher Asset Management LLC. Company insiders that have sold Integra LifeSciences company stock in the last year include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Richard E Caruso, Stuart Essig, and Tru St Partnership, LP.
View insider buying and selling activity for Integra LifeSciences
or view top insider-selling stocks.

Which major investors are buying Integra LifeSciences stock?

IART stock was bought by a variety of institutional investors in the last quarter, including Eaton Vance Management, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, GW&K Investment Management LLC, Bank of Nova Scotia, Champlain Investment Partners LLC, The Manufacturers Life Insurance Company, and Point72 Asset Management L.P..
View insider buying and selling activity for Integra LifeSciences
or or view top insider-buying stocks.

How do I buy shares of Integra LifeSciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Integra LifeSciences' stock price today?

One share of IART stock can currently be purchased for approximately $69.68.

How much money does Integra LifeSciences make?

Integra LifeSciences has a market capitalization of $5.89 billion and generates $1.37 billion in revenue each year. The life sciences company earns $133.89 million in net income (profit) each year or $2.45 on an earnings per share basis.

How many employees does Integra LifeSciences have?

Integra LifeSciences employs 3,700 workers across the globe.

What is Integra LifeSciences' official website?

The official website for Integra LifeSciences is

Where are Integra LifeSciences' headquarters?

Integra LifeSciences is headquartered at 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536.

How can I contact Integra LifeSciences?

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.